Charnwood Molecular appoints Director of DMPK
Charnwood Molecular, a leading UK-based pre-clinical discovery CRO serving the global pharmaceutical and biotechnology market, has appointed Laie Abello as its new Director of DMPK.
The appointment ideally positions Charnwood Molecular as a fully integrated drug discovery solution provider. Sitting alongside the company’s existing expertise and services across bioscience, medicinal chemistry, computational chemistry and process research and development, the DMPK department, under Laie’s management, will allow the company to further establish itself as the integrated discovery and development CRO of choice for its global client base.
Laie joins Charnwood Molecular from BenevolentAI where she was a Principal Scientist. Following her university education in Spain, Laie started her career at Almirall in Barcelona in 2010 as a Junior Scientist in DMPK. She moved to Almac Discovery in Belfast in 2012 where she was involved in setting up their new DMPK department, before moving to Xenogesis at BioCity, Nottingham in 2015, which was then acquired by Sygnature Discovery in September of 2020.
As a former Team Leader and Senior Scientist at both Xenogesis and Sygnature, Laie has extensive experience of setting up DMPK services and of working across integrated projects with a wide range of international clients.
Laie joins the DMPK department, which is based alongside Charnwood Molecular’s Biology and Medicinal Chemistry departments in its world-class facilities at Charnwood Campus, Loughborough. The DMPK department continues to grow to meet increasing demand from global clients of Charnwood Molecular’s services, with the company currently recruiting DMPK Scientists to expand the division.
“Laie’s appointment is the latest in a long line of developments which will further establish Charnwood Molecular as the integrated discovery and development CRO of choice for our global client base” stated Steve Allin, Chief Executive Officer of Charnwood Molecular. “We look forward to welcoming her to our ever-expanding DMPK department” he added.
“I am delighted to be joining Charnwood Molecular at such an exciting time in its development” said Laie Abello. “The world class facilities on offer at Charnwood Campus and the company’s extensive expansion plans make it the ideal time to become part of the team” she added.
Charnwood Molecular is ideally placed now to offer an ever-expanding number of services.
